Acta clinica Croatica, Vol. 39 No. 2, 2000.
Stručni rad
Role of Transurethral Resection of Superficial Bladder Tumors
Jordan Dimanovski
Alek Popović
Sažetak
Thirty percent all primary superficial bladder cancers do not recur at all, and hence do not need adjuvant treatment. Therefore, the most important is use is proper selection of patients who need adjuvant measures. Cystoscopy findings three months after transurethral resection (TUR) are of paramount importance. If there is no recurrence, patients are in a good prognosis group and need no further prophylactic measures. Recurrence assessed at that point requires maintance therapy. Because of the low toxicity and defendable scientific background after any TUR of a tumor that appears superficial to the clinician, a single administration of a chemotherapeutic agent can be used within three days of operation in order to prevent tumor cell seeding in the wound bed or elsewhere in the bladder. After resection of any pT1 (grade III) or Tis tumor, BCG maintenance therapy is appropriate. The remainder of pTa/pT1 (grade I and II) patients should be treated with intravesical chemotherapy in case of recurrence at three months. For patients who fail to respond to BCG treatment of pT1 ( grade III) or Tis and who are candidates for radical cystectomy, a new oral agent bromopirin with interferon inducing properties appears to offer some new hope. Patients with persistent positive high grade malignant citology are candidates for this new treatment.
Ključne riječi
Bladder neoplasms; Bladder neoplasms - surgery; Bladder neoplasms - prevention
Hrčak ID:
14956
URI
Datum izdavanja:
1.6.2000.
Posjeta: 1.419 *